Abemaciclib does not increase the corrected QT interval in healthy participants

• Päätekijät: Jill C. Chappell (Tekijä), Alan Y. Chiang (Tekijä), Jane Royalty (Tekijä), Hugh Coleman (Tekijä), Palaniappan Kulanthaivel (Tekijä), P. Kellie Turner (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Wiley, 2023-09-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract Abemaciclib is an orally administered, potent, and selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6, approved for advanced or metastatic breast cancer. This study aimed to use an exposure-response approach to investigate the effect of abemaciclib and its active metabol...